Arrowhead Pharmaceuticals (NASDAQ:ARWR) Announces Quarterly Earnings Results

Arrowhead Pharmaceuticals (NASDAQ:ARWR) released its quarterly earnings data on Monday. The biotechnology company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.65), MarketWatch Earnings reports. Arrowhead Pharmaceuticals had a negative return on equity of 28.00% and a negative net margin of 116.97%. During the same period in the previous year, the firm posted ($0.48) earnings per share.

Arrowhead Pharmaceuticals stock opened at $70.89 on Wednesday. The stock has a market cap of $7.39 billion, a PE ratio of -57.63 and a beta of 1.14. The stock has a 50-day moving average price of $66.91 and a 200 day moving average price of $69.40. Arrowhead Pharmaceuticals has a 52 week low of $56.05 and a 52 week high of $93.66.

Several research analysts have issued reports on ARWR shares. TheStreet upgraded Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, November 4th. SVB Leerink increased their price objective on Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the stock a “market perform” rating in a research report on Tuesday. Chardan Capital cut their price objective on Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating for the company in a research report on Friday, August 6th. Finally, HC Wainwright raised their price target on Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, August 10th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from, the company has an average rating of “Buy” and an average price target of $88.09.

In related news, CEO Christopher Richard Anzalone sold 50,000 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, October 22nd. The stock was sold at an average price of $65.63, for a total transaction of $3,281,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Martin Javier San sold 19,500 shares of the firm’s stock in a transaction dated Friday, November 19th. The stock was sold at an average price of $69.31, for a total value of $1,351,545.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 89,500 shares of company stock valued at $5,945,295. 3.50% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in Arrowhead Pharmaceuticals stock. LPL Financial LLC grew its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 100.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,116 shares of the biotechnology company’s stock after purchasing an additional 9,579 shares during the period. LPL Financial LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,193,000 as of its most recent SEC filing. Institutional investors and hedge funds own 63.54% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.

Featured Story: How Do Mutual Funds Work?

Earnings History for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with's FREE daily email newsletter.